Copyright
©2014 Baishideng Publishing Group Inc.
World J Cardiol. Aug 26, 2014; 6(8): 706-712
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.706
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.706
Table 1 Renal artery stenting/angioplasty in resistant hypertension
Ref. | Size | Follow up period | Mean SBP reduction with stenting/ angioplasty | Mean SBP reduction with medical therapy | P value |
Cooper et al[3] (Coral trial) | 947 | 43 mo | 16.6 ± 21.2 | 15.6 ± 25.8 | 0.03 |
Van Jaarsveld et al[7] (DRASTIC trial) | 106 | 12 mo | 19 | 17 | 0.51 |
Plouin et al[5] (EMMA trial) | 49 | 6 mo | 12 ± 20 | 8 ± 16 | 0.46 |
Webster et al[6] | 135 | 3-54 mo | 34 | 8 | 0.018 |
- Citation: Lokhandwala A, Dhoble A. Transcatheter therapies for resistant hypertension: Clinical review. World J Cardiol 2014; 6(8): 706-712
- URL: https://www.wjgnet.com/1949-8462/full/v6/i8/706.htm
- DOI: https://dx.doi.org/10.4330/wjc.v6.i8.706